Ionis Pharmaceuticals (NASDAQ:IONS) Director B Lynne Parshall Sells 5,000 Shares

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Director B Lynne Parshall sold 5,000 shares of the business’s stock in a transaction on Wednesday, February 11th. The shares were sold at an average price of $82.72, for a total value of $413,600.00. Following the transaction, the director owned 56,344 shares of the company’s stock, valued at approximately $4,660,775.68. The trade was a 8.15% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Ionis Pharmaceuticals Stock Performance

Shares of Ionis Pharmaceuticals stock opened at $80.60 on Friday. The company has a quick ratio of 2.78, a current ratio of 2.79 and a debt-to-equity ratio of 0.96. The stock’s fifty day moving average is $80.70 and its two-hundred day moving average is $69.12. Ionis Pharmaceuticals, Inc. has a 52 week low of $23.95 and a 52 week high of $86.74. The company has a market capitalization of $13.06 billion, a PE ratio of -47.69 and a beta of 0.29.

Hedge Funds Weigh In On Ionis Pharmaceuticals

Several institutional investors have recently bought and sold shares of IONS. Capital World Investors lifted its holdings in Ionis Pharmaceuticals by 41.2% during the fourth quarter. Capital World Investors now owns 17,961,299 shares of the company’s stock worth $1,420,918,000 after buying an additional 5,238,571 shares during the period. Adage Capital Partners GP L.L.C. raised its position in shares of Ionis Pharmaceuticals by 253.3% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 3,800,000 shares of the company’s stock worth $150,138,000 after acquiring an additional 2,724,400 shares in the last quarter. Franklin Resources Inc. raised its position in shares of Ionis Pharmaceuticals by 19,941.6% in the 4th quarter. Franklin Resources Inc. now owns 1,321,345 shares of the company’s stock worth $104,532,000 after acquiring an additional 1,314,752 shares in the last quarter. Marshall Wace LLP lifted its stake in shares of Ionis Pharmaceuticals by 7,219.3% during the 3rd quarter. Marshall Wace LLP now owns 958,829 shares of the company’s stock worth $62,727,000 after purchasing an additional 945,729 shares during the last quarter. Finally, American Century Companies Inc. boosted its position in Ionis Pharmaceuticals by 190.3% during the third quarter. American Century Companies Inc. now owns 1,372,225 shares of the company’s stock valued at $89,771,000 after purchasing an additional 899,476 shares in the last quarter. 93.86% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on IONS shares. Needham & Company LLC boosted their price objective on shares of Ionis Pharmaceuticals from $78.00 to $90.00 and gave the company a “buy” rating in a research report on Thursday, October 30th. Royal Bank Of Canada lifted their price target on shares of Ionis Pharmaceuticals from $82.00 to $95.00 and gave the company an “outperform” rating in a research note on Wednesday, December 17th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Ionis Pharmaceuticals in a report on Thursday, January 22nd. Bank of America raised their price objective on Ionis Pharmaceuticals from $86.00 to $97.00 and gave the stock a “buy” rating in a report on Tuesday, December 9th. Finally, Leerink Partners lifted their target price on Ionis Pharmaceuticals from $85.00 to $100.00 and gave the company an “outperform” rating in a research report on Monday, December 15th. One analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $86.95.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc is a biotechnology company focused on the discovery and development of RNA-targeted therapies designed to modulate gene expression. The company’s proprietary antisense oligonucleotide (ASO) technology enables the selective binding of short synthetic strands of nucleic acids to messenger RNA (mRNA), thereby inhibiting or altering the production of disease-causing proteins. Ionis’ pipeline spans a range of therapeutic areas, including neurological disorders, cardiovascular conditions, metabolic diseases and rare genetic disorders.

Since its founding in 1989 by Dr.